Janus Henderson Group PLC Buys 167,501 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Janus Henderson Group PLC increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 17.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,143,830 shares of the biopharmaceutical company’s stock after purchasing an additional 167,501 shares during the quarter. Janus Henderson Group PLC’s holdings in Cytokinetics were worth $60,399,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Darwin Global Management Ltd. purchased a new position in Cytokinetics in the 2nd quarter valued at approximately $246,074,000. Integral Health Asset Management LLC grew its stake in Cytokinetics by 122.2% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $54,180,000 after buying an additional 550,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Cytokinetics by 42.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company’s stock valued at $69,769,000 after buying an additional 395,709 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Cytokinetics by 38.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,212,886 shares of the biopharmaceutical company’s stock valued at $64,040,000 after buying an additional 339,373 shares in the last quarter. Finally, Checkpoint Capital L.P. grew its stake in Cytokinetics by 145.7% in the 3rd quarter. Checkpoint Capital L.P. now owns 466,813 shares of the biopharmaceutical company’s stock valued at $24,648,000 after buying an additional 276,813 shares in the last quarter.

Insider Buying and Selling at Cytokinetics

In other news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $52.14, for a total transaction of $260,700.00. Following the completion of the sale, the chief executive officer now owns 397,456 shares in the company, valued at approximately $20,723,355.84. The trade was a 1.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $52.10, for a total transaction of $380,330.00. Following the completion of the transaction, the executive vice president now directly owns 118,920 shares in the company, valued at $6,195,732. The trade was a 5.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,994 shares of company stock valued at $3,427,975 over the last ninety days. Corporate insiders own 3.40% of the company’s stock.

Cytokinetics Trading Down 0.1 %

NASDAQ CYTK opened at $50.40 on Friday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The firm has a market cap of $5.95 billion, a PE ratio of -9.37 and a beta of 0.80. The company has a 50 day moving average price of $53.11 and a 200 day moving average price of $54.20. Cytokinetics, Incorporated has a 52 week low of $32.50 and a 52 week high of $110.25.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. Cytokinetics’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.35) EPS. As a group, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Monday. JMP Securities reissued a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Wednesday, September 4th. Royal Bank of Canada started coverage on shares of Cytokinetics in a research note on Friday, November 8th. They issued an “outperform” rating and a $80.00 price target for the company. Mizuho upped their price objective on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the company an “overweight” rating in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average price target of $83.93.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.